• Traitements

  • Traitements systémiques : applications cliniques

  • Lymphome

Brentuximab vedotin

Cet article passe en revue les travaux récents sur le brentuximab vedotin dans le traitement des lymphomes hodgkiniens, des lymphomes anaplasiques à grandes cellules et autres lymphomes CD30+

Brentuximab vedotin (SGN-35), an intravenously administered CD30-specific antibody-drug conjugate, has recently been approved by the U.S. Food and Drug Administration for two indications, including (1) patients with Hodgkin's lymphoma (HL) relapsing after autologous stem cell transplantation (ASCT), or after two multi-drug regimens in HL patients who are not candidates for ASCT; and (2) patients with systemic anaplastic large cell lymphoma (ALCL) who failed at least one prior multi-drug chemotherapy regimen. HL and ALCL patients treated with brentuximab vedotin demonstrated markedly high response rates for a single agent, exceeding 70% and 80% for HL and ALCL, respectively. The complete response rate was equally as impressive, at 34% and 57% for HL and ALCL, respectively. These and results from many upcoming clinical trials, where brentuximab vedotin is being investigated in the frontline setting, promise to profoundly change how we manage the CD30 positive lymphoproliferative malignancies. The mechanism of action, preclinical antitumor activity, and clinical activity of brentuximab vedotin against HL, ALCL, and other CD30 expressing lymphoma are reviewed.

Clinical Cancer Research

Voir le bulletin